Why Organon Is A Top Pick For Income Investors
Organon pleasantly surprised me with its financial results for Q4 2024. Read why I believe OGN is an attractive stock for ...
Letters: Tribune Editorial Board does a disservice to Mahmoud Khalil and protesters
I disagree with the editorial board’s characterization of Mahmoud Khalil as “a supporter of Hamas” rather than as a supporter ...
'Deep discounted' ideas in healthcare amid recent volatility - KeyBanc
KeyBanc Capital Markets shared a selected group of “deep discounted” stocks that look attractive amid the recent market ...
Pfizer reinvents sales strategy
Pfizer’s CEO Albert Bourla has revamped sales tactics, leading to a 31% rise in U.S. sales of Nurtec migraine medication, reports The Wall Street Journal.